ArticleFrontiers in immunology2022
A recombinant
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Montelukast alleviates levels of inflammatory factors and chemokines in patients with allergic rhinitis.Inflammopharmacology · 2026Trial
- Long-Term Administration of BTH2 Hypoallergenic Vaccine Candidate Induces Hallmarks of Allergen Immunotherapy in Murine Model ofBiomedicines · 2025Article
- Bibliometric and visual analysis of drug-specific immunotherapy from 1990 to 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma.NPJ vaccines · 2025Article
- The role of major allergens Art v 1 and Art v 3 inFrontiers in immunology · 2025Article
- Intranasal monoclonal antibodies to mugwort pollen reduce allergic inflammation in a mouse model of allergic rhinitis and asthma.Frontiers in immunology · 2025Article
- Three Artemisia pollens trigger the onset of allergic rhinitis via TLR4/MyD88 signaling pathway.Molecular biology reports · 2024Article
- Long-acting anti-inflammatory injectable DEX-Gel with sustained release and self-healing properties regulates TJournal of nanobiotechnology · 2024Article
- Exposure to unmethylated CpG oligonucleotides disrupts blood pressure circadian rhythms and placental clock gene network in pregnant rats.American journal of physiology. Heart and circulatory physiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Allergic rhinitis is an important risk factor for bronchial asthma. Allergen-specific immunotherapy (ASIT) is the gold standard for treatment of allergic rhinitis, conjunctivitis, and asthma. A disadvantage of current ASIT methods is the length of therapy which requires numerous allergen administrations. The success of ASIT is determined by its schedule, which, depending on the vaccine and type of allergy, can be pre-seasonal (before the allergy season begins), combined pre/co-seasonal (during the allergy season) etc. The aim of the present study was to evaluate a vaccine based on recombinant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.